Adam M Veness's Net Worth
$2.09 Million
Who is Adam M Veness?
Adam M Veness has an estimated net worth of $2.09 Million. This is based on reported shares across multiple companies, which include Dianthus Therapeutics, Inc. /DE/, Cyteir Therapeutics, Inc., and ACCELERON PHARMA INC.
SEC CIK
Adam M Veness's CIK is 0001778623
Past Insider Trading and Trends
2021 was Adam M Veness's most active year for acquiring shares with 5 total transactions. Adam M Veness's most active month to acquire stocks was the month of December. 2021 was Adam M Veness's most active year for disposing of shares, totalling 18 transactions. Adam M Veness's most active month to dispose stocks was the month of August. 2020 saw Adam M Veness paying a total of $167,820.00 for 36,703 shares, this is the most they've acquired in one year. In 2021 Adam M Veness cashed out on 112,319 shares for a total of $1,640,227.44, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Dianthus Therapeutics, Inc. /DE/ (DNTH) Snapshot price: $26.62
SVP, General Counsel and Sec.
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 23
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 24
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Cyteir Therapeutics, Inc. (CYT) No price found
General Counsel
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 3
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 2
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
ACCELERON PHARMA INC No price found
SVP, General Counsel and Sec.
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -100.00% | -23.42K |
—
|
—
|
0
|
Nov 19
| |||
Form 4
| +23.78% | 4.5K |
$29.37 | $132,165.00 | 23.42K |
Nov 9
| |||
Form 4
|
—
|
0
|
$91.32 | -$781,208.50 | 18.92K |
Scheduled
|
Sep 21
| ||
Form 4
| -9.56% | -2.00K |
$129.81 | -$259,624.32 | 18.92K |
Scheduled
|
Sep 7 - Sep 9
| ||
Form 4
| -0.51% | -108.00 |
$126.69 | -$13,682.52 | 20.92K |
Jun 7
| |||
Form 4
| +30.12% | 4.87K |
—
|
—
| 21.03K |
Jan 29
| |||
Form 4
| -15.65% | -3.00K |
$123.11 | -$369,088.10 | 16.16K |
Scheduled
|
Jan 4 - Jan 5
| ||
Form 4
| -9.45% | -2.00K |
$89.50 | -$179,003.85 | 19.16K |
Scheduled
|
Sep 8
| ||
Form 4
|
—
|
0
|
$56.78 | -$345,688.92 | 21.16K |
Scheduled
|
Apr 8
| ||
Form 4
| +43.06% | 6.37K |
—
|
—
| 21.16K |
Jan 22
| |||
Form 4
| -8.13% | -1.31K |
$51.76 | -$67,754.47 | 14.79K |
Scheduled
|
Jan 2 - Jan 3
| ||
Form 4
| -4.87% | -824.00 |
$45.20 | -$37,241.43 | 16.1K |
Scheduled
|
Sep 10
| ||
Form 4
| -16.18% | -3.27K |
$45.00 | -$147,060.00 | 16.93K |
Scheduled
|
Aug 9
| ||
Form 4
| -2.60% | -538.00 |
$40.71 | -$21,901.98 | 20.19K |
Scheduled
|
Jul 16
| ||
Form 4
| +5.60% | 1.1K |
—
|
—
| 20.73K |
Jun 5
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||